Phase II clinical study on the GEMOX regimen as second- line therapy for advanced ovarian cancer
| Autor: | Wen-Jun Chen, Jian-Ping Xiong, Lin-Jia Zhu, Lian-Ping Zhang, Wei E. Zheng, Shao-Fei Yuan |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Adult
Cancer Research medicine.medical_specialty Organoplatinum Compounds Epidemiology Urology Deoxycytidine Antineoplastic Combined Chemotherapy Protocols Medicine Humans Adverse effect Survival rate Aged Neoplasm Staging Ovarian Neoplasms business.industry Public Health Environmental and Occupational Health GEMOX regimen Middle Aged medicine.disease Prognosis Adenocarcinoma Mucinous Gemcitabine Surgery Oxaliplatin Cystadenocarcinoma Serous Endometrial Neoplasms Clinical trial Survival Rate Oncology Case-Control Studies Quality of Life Adenocarcinoma Female business Ovarian cancer medicine.drug Adenocarcinoma Clear Cell Follow-Up Studies |
| Zdroj: | Asian Pacific journal of cancer prevention : APJCP. 14(6) |
| ISSN: | 2476-762X |
| Popis: | To investigate the effectiveness and adverse effects of gemcitabine by fixed-dose rate infusion plus oxaliplatin (GEMOX regimen) as second-line therapy for advanced ovarian cancer.64 patients with advanced ovarian cancer were divided into an experimental group (44 cases) and a control group (20 cases). The experimental group was treated with continuous intravenous infusion of gemcitabine at 1000 mg/m(2) with a fixed-dose rate of 10 mg/m(2)/min, on days 1 and 8 and oxaliplatin at 100 mg/m(2) on day 1, IVGTT, repeated every 3 weeks. The control group was treated with intravenous infusion of gemcitabine at 1000 mg/m(2) within 30 min on days 1 and and oxaliplatin at 100 mg/m(2) on day 1, IVGTT, again repeated every 3 weeks. CT scans or MRI were used for review every 1-2 cycles.The effective rate in the experimental group was significantly high than control group (43.2% vs 35.0%; P0.05), with no obvious difference of hematologic or non-hematologic toxicity between the two groups (P0.05).GEMOX regimen is very effective to treat advanced ovarian cancer, with low toxicity, good tolerance and improved life quality in patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|